Merck raised its full-year revenue outlook after new drug sales outpaced Wall Street expectations, even as the pharmaceutical giant lowered its profit guidance to absorb charges linked to a recent biotech acquisition.
The company’s second-quarter performance was buoyed by growth across newer products, a development Merck is counting on as it prepares for the eventual patent expiration of its blockbuster cancer immunotherapy Keytruda later this decade.
Despite the stronger top-line results, Merck cut its earnings forecast to account for a charge tied to its acquisition of Terns Pharmaceuticals, a biotech firm the company purchased to bolster its development pipeline. Deal-related charges of this kind reduce reported profit even when underlying operations remain healthy.
The mixed guidance reflects a broader strategy at Merck to diversify its revenue base ahead of a looming patent cliff. Keytruda, which generates a substantial share of the company’s sales, faces the loss of exclusivity toward the end of the decade, prompting a wave of dealmaking and cost discipline across the business.
Earlier plans to reduce costs by $3 billion by 2027 underscore the pressure the company faces to protect margins while investing in future growth drivers.
Merck’s acquisition of Terns adds to a series of pipeline-building moves as management seeks to identify products capable of offsetting an eventual decline in Keytruda revenue. The near-term hit to earnings, executives have signaled, is a trade-off for longer-term strategic positioning.
The results place Merck among several major drugmakers navigating a period of shifting fortunes, as revenue growth from newer therapies is weighed against acquisition costs and pricing pressures in key markets.
Investors will be watching how quickly the company’s newer products can scale and whether the Terns assets deliver on their promise. For now, the raised revenue outlook suggests Merck’s core commercial engine remains robust even as one-time charges cloud the profit picture.